QuantumPharm, Inc. (2228) AI Stock Analysis

• Market Cap: HK$47.27B
• Dividend Yield: N/A
• Average Volume (3M): 143.30M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 243.78%
• EPS Growth: 97.15%
• Country: HK
• Employees: 809
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.02
• Shares Outstanding: 4,302,922,000
• 10 Day Avg. Volume: 160,836,692
• 30 Day Avg. Volume: 143,301,077
• PEG Ratio: 0.00
• Price to Book (P/B): 2.72
• Price to Sales (P/S): 40.47
• P/FCF Ratio: -20.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: HK$9.50 ▲(0.53% Upside)

QuantumPharm, Inc. faces significant financial challenges, with persistent losses and negative cash flows being the most critical issues. The technical analysis suggests weak momentum, further weighing on the stock's outlook. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield. Despite some improvements in debt levels and equity position, the overall financial health remains a concern.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product acceptance, supporting long-term business expansion and competitiveness.

Partnerships

Strategic partnerships expand research capabilities and distribution networks, strengthening market position and fostering innovation.

Gross Profit Margin Improvement

Improved gross profit margin suggests better cost management and pricing power, enhancing long-term profitability potential.

Negative Factors

Persistent Losses

Ongoing losses highlight challenges in achieving profitability, which could hinder long-term financial stability and growth.

Negative Cash Flows

Negative cash flows limit the company's ability to invest in growth opportunities and may necessitate external financing, affecting financial health.

Financial Instability

Concerns about financial instability could impact the company's ability to secure favorable financing terms, affecting long-term operations.

QuantumPharm, Inc. Business Overview & Revenue Model

Company Description

XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company's drug discovery solutions cover the whole drug discovery and research process, including target validation, hit identification, lead generation, lead optimization, and PCC nomination covering various modalities, which comprise small molecules, antibodies, peptides, ADC, and PROTAC. Its intelligent automation solutions focus on AI- and automation-enabled novel drug and materials discovery and research. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.

How the Company Makes Money

QuantumPharm generates revenue primarily through the commercialization of its pharmaceutical products, which include both proprietary drugs and those developed in collaboration with larger pharmaceutical companies. Key revenue streams include direct sales of approved drugs, licensing agreements for its proprietary technologies, and milestone payments from partnerships for co-development projects. Significant partnerships with major pharmaceutical firms enhance its research capabilities and provide access to broader distribution networks, contributing to its earnings. Additionally, the company may engage in government and private research grants that fund specific projects, further diversifying its revenue sources.

QuantumPharm, Inc. Financial Statement Overview

Summary

QuantumPharm, Inc. shows strong revenue growth but struggles with profitability, as indicated by negative net profit margins and cash flows. Improvements in debt levels and equity position provide some stability, but operational efficiency and financial sustainability remain concerns.

Income Statement

QuantumPharm, Inc. has shown significant revenue growth from 2019 to 2024, yet the company struggles with profitability. Gross Profit Margin improved to 46.31% in 2024 from 27.66% in 2023, but the company continues to incur substantial net losses, with a Net Profit Margin of -569.33% in 2024. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has made notable improvements in its balance sheet, reducing total debt significantly from 2023 to 2024. The Debt-to-Equity Ratio has improved due to a positive equity position in 2024. However, the Equity Ratio remains a concern, reflecting potential financial instability.

Cash Flow

Operating Cash Flow has improved slightly, yet remains negative, impacting the company's ability to generate positive Free Cash Flow. Despite the improvement in financing activities, the Free Cash Flow to Net Income Ratio remains unfavorable, indicating ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2019
Income Statement
Total Revenue	680.88M	266.43M	174.42M	133.35M	62.80M	0.00
Gross Profit	511.39M	123.43M	48.24M	66.09M	32.78M	0.00
EBITDA	-243.20M	-631.38M	-1.78B	-1.38B	-2.11B	-9.84M
Net Income	-196.79M	-1.52B	-1.91B	-1.44B	-2.14B	-36.03M
Balance Sheet
Total Assets	7.72B	4.35B	4.01B	4.32B	4.38B	8.44M
Cash, Cash Equivalents and Short-Term Investments	5.32B	3.10B	2.83B	3.47B	3.83B	8.44M
Total Debt	366.10M	148.76M	11.04B	9.45B	7.83B	159.05M
Total Liabilities	689.47M	362.43M	11.25B	9.63B	7.99B	219.45M
Stockholders Equity	6.99B	3.96B	-7.27B	-5.33B	-3.61B	-211.01M
Cash Flow
Free Cash Flow	-475.64M	-536.79M	-698.20M	-627.83M	-417.42M	655.00K
Operating Cash Flow	-417.87M	-478.68M	-567.56M	-429.10M	-253.75M	655.00K
Investing Cash Flow	-1.69B	74.09M	735.58M	-2.76B	-70.47M	33.00K
Financing Cash Flow	3.13B	840.00M	-25.89M	57.99M	2.48B	0.00

QuantumPharm, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Negative. The current price of 9.45 is below the 20-day moving average (MA) of 10.30, below the 50-day MA of 11.38, and above the 200-day MA of 7.78, indicating a neutral trend. The MACD of -0.48 indicates Positive momentum. The RSI at 36.38 is Neutral, neither overbought nor oversold. The STOCH value of 20.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2228.

QuantumPharm, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	73 Outperform	HK$88.15B	58.95	19.62%	―	―	―
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
2502	54 Neutral	HK$710.76M	―	-6.64%	―	2.76%	-293.57%
2509	46 Neutral	HK$4.76B	―	-64.62%	―	―	―
2228	42 Neutral	HK$47.27B	-171.45	-3.55%	―	243.78%	97.15%
2498	38 Underperform	HK$15.91B	-33.18	-11.44%	―	―	―
2511	36 Underperform	HK$1.78B	-5.03	-67.27%	―	―	47.42%

QuantumPharm, Inc. Corporate Events

XtalPi Enters Consumer Healthcare with AI-Developed Hair Growth Molecules

XtalPi Holdings Limited has announced the successful development of two new molecules, Remeanagen™ and AquaKine™, for hair growth and hair loss prevention using its AI molecular discovery platform. These molecules, combined in the product Groland, have shown superior performance in human trials and received key international certifications, marking XtalPi’s entry into the consumer healthcare sector. This development underscores the company’s commitment to leveraging AI for creating both life-saving drugs and consumer products that enhance daily life.

XtalPi’s Ailux Partners with Eli Lilly for AI-Driven Antibody Development

XtalPi’s subsidiary, Ailux, has announced a strategic collaboration with Eli Lilly to enhance the development of bispecific antibodies using AI-driven technology. This partnership allows Lilly to access Ailux’s advanced antibody engineering platform, potentially leading to significant milestone payments and a total collaboration value of up to $345 million, marking a substantial impact on XtalPi’s industry positioning and stakeholder interests.

XtalPi Holdings Clarifies Interim Results, Corrects Earnings Figures

XtalPi Holdings Limited, a company listed on the Hong Kong Stock Exchange, issued a clarification announcement regarding its interim results for the six months ended June 30, 2025. The company corrected errors in the reported number of ordinary shares and earnings per share figures, which were initially misstated in their interim results announcement. The corrected figures indicate a higher earnings per share than previously reported, which may positively impact stakeholders’ perception of the company’s financial performance.